Showing 6491-6500 of 7174 results for "".
- ChloraDerm Launches Pediatric Offeringhttps://practicaldermatology.com/news/chloraderm-launches-pediatric-offering/2458683/entrotech life sciences (ELS) announced the availability of FDA-Cleared ChloraDerm in a new 1.75"x 1.75" configuration, ideal for pediatric patient use. ChloraDerm is the only transparent film dressing containing the Chlorhexidine Advantage, a safe, colophony-and acid-free, edge-t
- Neutrogena® Launches First-Ever Global Beauty Campaignhttps://practicaldermatology.com/news/neutrogena-launches-first-ever-global-beauty-campaign/2458684/Neutrogena® is set to debut their first-ever global campaign: “Neutrogena. See What’s Possible.™” A commercial voiced by Brand Ambassador and creative consultant Kerry Washington will fe
- Galderma Mans Up with New Cetaphil Line for Menhttps://practicaldermatology.com/news/cetaphils-newest-line-targets-men/2458690/Galderma Laboratories, L.P is manning up with the launch of a new skin care line for men. The Cetaphil® Men line comprises Cetaphil® Men Daily Face Wash, Cetaphil® M
- Sweet Acne Cure: Kanuka Honey from New Zealand May Eradicate Acnehttps://practicaldermatology.com/news/sweet-acne-cure-kanuka-honey-from-new-zealand-may-eradicate-acne/2458693/Kanuka honey may help out the brakes on acne, new research suggests. In the study of Honevo®, developed by New Zealand pharmaceutical company HoneyLab, twice as many participants had an imp
- New AAD Acne Guidelines Call for Combination Therapyhttps://practicaldermatology.com/news/new-aad-acne-guidelines-call-for-combination-therapy/2458695/Combination therapy is the way forward for treating moderate-to-mild acne, according to new guidelines from The American Academy of Dermatology. For example, antibiotics should be used with topical acne therapy, and patients should continue using topical treatments to manage their c
- Hidradenitis Suppurativa Ups Risk of Adverse CV Eventshttps://practicaldermatology.com/news/hidradenitis-suppurativa-ups-risk-of-adverse-cv-events/2458696/Hidradenitis suppurativa (HS) may increase risk for adverse cardiovascular outcomes, a new study suggests. HS has been associated with cardiovascular risk factors, such as smoking and obesity, but the risk of cardiovascular disease in patients with HS was unknown. The new study
- Endo International Launches New Phase 2b Study of CCH for Cellulitehttps://practicaldermatology.com/news/endo-international-launches-new-phase-2b-study-of-cch-for-cellulite/2458699/A Phase 2b study of collagenase clostridium histolyticum (CCH) for the treatment of as cellulite is about to get started, Endo International plc reports. CCH is intended to target and lyse collagen tethers with the goal of releasing the skin di
- Cipher's Sitavig Accepted for Review by Health Canadahttps://practicaldermatology.com/news/ciphers-sitavig-accepted-for-review-by-health-canada/2458701/Cipher Pharmaceuticals Inc.’s New Drug Submission for Sitavig has been accepted for review by Health Canada. Sitavig (acyclovir mucoadhesive buccal tablets) is proposed for the treatment of recurrent herpes labialis in adults. In the United States, Sitavig® is approve
- FDA Accepts Allergan's sNDA for TEFLARO Use in Childrenhttps://practicaldermatology.com/news/fda-accepts-allergans-snda-for-teflaro-use-in-children/2458700/The U.S. Food and Drug Administration (FDA) has accepted Allergan’s supplemental New Drug Application (sNDA) for IV antibacterial TEFLARO® (ceftaroline fosamil). If approved, this filing will expand the label of TEFLARO beyond adults to include children two months of age a
- Interferon Not Beneficial for Most Stage III Melanomahttps://practicaldermatology.com/news/interferon-not-beneficial-for-most-stage-iii-melanoma/2458703/Most stage III melanoma patients do not benefit from treatment with interferon, according to final results for the Sunbelt Melanoma Trial, published online in the Jour